The NASPP Blog

Convictions

Over the past week the final verdict came in for two of the cases I blogged about on April 15th.

First, former CEO of KB Home, Bruce Karatz, was convicted for concealing the company’s backdating scheme and faces up to 80 years in federal prison. Mr. Karatz was found guilty on four counts including making false statements on a quarterly report filed with the SEC and making false statements to the company’s outside accounting firm, but was acquitted of 16 other counts including three counts of securities fraud (the most serious charges against him). Mr. Karatz, in pleading non-guilty to all charges, had claimed that he was falsely targeted as part of the governments crack-down on illegal back-dating. With only four out of 20 charges resulting in a conviction, it looks like even the testimony against him from the former KB Homes HR Director, Gary Ray, wasn’t enough for the SEC to get the big win they were looking for on this one. (See this Rueters article.)

Alternatively, former Maxim Integrated Product’s CFO, Carl Jasper was found guilty on eight out of 11 counts against him. Mr. Jasper had claimed that the backdating scheme was above his pay grade (so to speak) and that former CEO, Jack Gifford, was an unstoppable force heading up the practice. (See this Business Journal article.)

Both Mr. Karatz and Mr. Jasper intend to challenge their convictions.

Options Prevail!

Almost exactly one year after rejecting a proposal to ban stock options to senior executive officers (See this Associated Press article.), Pfizer shareholders got a second opportunity to vote on a very similar proposal. Once again, the proposal to eliminate all future option grants to executive officers was overwhelmingly rejected.

This year, the proposal was being brought by activist shareholder Evelyn Y. Davis, who obviously favors restricted stock over options, blaming the recent fluctuations in the market on “shenanigans” stemming from the granting of stock options. Coincidentally, shareholders did vote to give themselves an advisory vote on executive compensation, adding Pfizer to the list of companies engaging in some type of “say on pay.” (See this Yahoo! Finance article.)

I was thinking about this vote when I saw our own Broc Romanek’s April 17th Advisor’s Blog entry on CompensationStandards.com. He brought it to my attention that the Council of Institutional Investors published a checklist of the “Top 10 Red Flags to Watch for When Casting an Advisory Vote on Executive Compensation”. On that list is a call for stock options to be linked to performance, an approach to granting options that Ms. Davis seems to have missed.

If you’re looking for the best information available on executive compensation, you’ll be excited to know that your registration for the 18th Annual NASPP Conference includes a special bonus access to the 7th Annual Executive Compensation Conference! If you aren’t already registered, don’t miss out on the $200 discount that we are offering through May 14th. Register today!

-Rachel